Publisher
Springer International Publishing
Reference247 articles.
1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). [Internet]. 2019. Available from: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b. Accessed 13 Nov 2022.
2. Global Burden of Disease Studies. Implications for mental and substance use disorders. Health Aff. 2016;35(6):1114–20. https://doi.org/10.1377/hlthaff.2016.0082.
3. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–46. https://doi.org/10.1001/jama.2016.16885.
4. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62. https://doi.org/10.1055/s-0037-1600991.
5. Kim JA, Ceccarelli R, Lu CY. Pharmacogenomic biomarkers in US FDA-approved drug labels (2000–2020). J Pers Med. 2021;11(3). https://doi.org/10.3390/jpm11030179.